Elucidating the role of protein kinase C in chronic lymphocytic leukaemia

Hematological Oncology

Volumn 24, Issue 3, 2006, Pages 134-138

  Michie, Alison M ^a   Nakagawa, Rinako ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

Apoptosis; Chronic lymphocytic leukaemia; PKC inhibitors; Protein kinase C

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; 7 HYDROXYSTAUROSPORINE; ANTINEOPLASTIC AGENT; AT 514; BISINDOLYLMALEIMIDE; BRYOSTATIN 1; CAMPTOTHECIN DERIVATIVE; CHLORAMBUCIL; DEXAMETHASONE; FLUDARABINE; INGENOL 3 ANGELATE; MIDOSTAURIN; NSC 606985; PEP 005; PHORBOL 13 ACETATE 12 MYRISTATE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE C; PROTEIN KINASE C INHIBITOR; ROTTLERIN; SERRATAMOLIDE; UNCLASSIFIED DRUG;

APOPTOSIS; CELL ACTIVATION; CELL DIFFERENTIATION; CELL SURVIVAL; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL TRIAL; CYTOTOXICITY; DOWN REGULATION; DRUG EFFICACY; DRUG MECHANISM; DRUG TARGETING; ENZYME ACTIVITY; HUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION; UPREGULATION;

1-PHOSPHATIDYLINOSITOL 3-KINASE; CELL SURVIVAL; ENZYME ACTIVATION; LEUKEMIA, LYMPHOCYTIC, CHRONIC; NEOPLASM PROTEINS; PROTEIN KINASE C; PROTEIN KINASE INHIBITORS; SIGNAL TRANSDUCTION;

EID: 33749264067     PISSN: 02780232     EISSN: 10991069     Source Type: Journal    
DOI: 10.1002/hon.789     Document Type: Review

References (47)

1. Gescher A. Staurosporine analogues-pharmacological toys or useful antitumour agents. Crit Rev Oncol Hematol 2000; 34: 127-135.
2. Clamp A, Jayson GC. The clinical development of the bryostatins. Anticancer Drugs 2002; 13: 673-683.
3. Yin JQ, Gao J, Shao R, Tian WN, Wang J, Wan Y. siRNA agents inhibit oncogene expression and attenuate human tumor cell growth. J Exp Ther Oncol 2003; 3: 194-204.
4. Bannerji R, Byrd JC. Update on the biology of chronic lymphocytic leukemia. Curr Opin Oncol 2000; 12: 22-29.
5. Kay NE, Hamblin TJ, Jelinek DF, et al. Chronic lymphocytic leukemia. Hematology (Am Soc Hematol Educ Program) 2002. 193-213.
6. Stevenson FK, Caligaris-Cappio F. Chronic lymphocytic leukemia: revelations from the B-cell receptor. Blood 2004; 103: 4389-4395.
7. Tan SL, Parker PJ. Emerging and diverse roles of protein kinase C in immune cell signaling. Biochem J 2003; 376: 545-552.
8. Nishizuka Y. Protein kinase C and lipid signaling for sustained cellular responses. Faseb J 1995; 9: 484-496.
9. Sun Z, Arendt CW, Ellmeier W, et al. PKC-theta is required for TCR-induced NF-kappaB activation in mature but not immature T lymphocytes. Nature 2000; 404: 402-407.
10. Leitges M, Schmedt C, Guinamard R, et al. Immunodeficiency in protein kinase cbeta-deficient mice. Science 1996; 273: 788-791.
11. Leitges M, Plomann M, Standaert ML, et al. Knockout of PKC alpha enhances insulin signaling through PI3K. Mol Endocrinol 2002; 16: 847-858.
12. Komada F, Nishikawa M, Uemura Y, Morita K, Hidaka H, Shirakawa S. Expression of three major protein kinase C isozymes in various types of human leukemic cells. Cancer Res 1991; 51: 4271-4278.
13. Alkan S, Huang Q, Ergin M, et al. Survival role of protein kinase C (PKC) in chronic lymphocytic leukemia and determination of isoform expression pattern and genes altered by PKC inhibition. Am J Hematol 2005; 79: 97-106.
14. Ringshausen I, Schneller F, Bogner C, et al. Constitutively activated phosphatidylinositol-3 kinase (PI-3K) is involved in the defect of apoptosis in B-CLL: association with protein kinase Cdelta. Blood 2002; 100: 3741-3748.
15. Ringshausen I, Oelsner M, Weick K, Bogner C, Peschel C, Decker T. Mechanisms of apoptosis-induction by rottlerin: therapeutic implications for B-CLL. Leukemia 2006; 20: 514-520.
16. Trushin SA, Pennington KN, Carmona EM, et al. Protein kinase Calpha (PKCalpha) acts upstream of PKCtheta to activate IkappaB kinase and NF-kappaB in T lymphocytes. Mol Cell Biol 2003; 23: 7068-7081.
17. Matassa AA, Kalkofen RL, Carpenter L, Biden TJ, Reyland ME. Inhibition of PKCalpha induces a PKCdelta-dependent apoptotic program in salivary epithelial cells. Cell Death Differ 2003; 10: 269-277.
18. Mandil R, Ashkenazi E, Blass M, et al. Protein kinase Calpha and protein kinase Cdelta play opposite roles in the proliferation and apoptosis of glioma cells. Cancer Res 2001; 61: 4612-4619.
19. Szallasi Z, Smith CB, Pettit GR, Blumberg PM. Differential regulation of protein kinase C isozymes by bryostatin 1 and phorbol 12-myristate 13-acetate in NIH 3T3 fibroblasts. J Biol Chem 1994; 269: 2118-2124.
20. Tötterman TH, Nilsson K, Sundström C. Phorbol ester-induced differentiation of chronic lymphocytic leukaemia cells. Nature 1980; 288: 176-178.
21. Barragán M, Bellosillo B, Campàs C, Colomer D, Pons G, Gil J. Involvement of protein kinase C and phosphatidylinositol 3-kinase pathways in the survival of B-cell chronic lymphocytic leukemia cells. Blood 2002; 99: 2969-2976.
22. Forbes IJ, Zalewski PD, Giannakis C, Cowled PA. Induction of apoptosis in chronic lymphocytic leukemia cells and its prevention by phorbol ester. Exp Cell Res 1992; 198: 367-372.
23. Bellosillo B, Dalmau M, Colomer D, Gil J. Involvement of CED-3/ICE proteases in the apoptosis of B-chronic lymphocytic leukemia cells. Blood 1997; 89: 3378-3384.
24. Drexler HG, Gignac SM, Jones RA, et al. Bryostatin 1 induces differentiation of B-chronic lymphocytic leukemia cells. Blood 1989; 74: 1747-1757.
25. al-Katib A, Mohammad RM, Dan M, et al. Bryostatin 1-induced hairy cell features on chronic lymphocytic leukemia cells in vitro. Exp Hematol 1993; 21: 61-65.
26. Varterasian ML, Mohammad RM, Shurafa MS, et al. Phase II trial of bryostatin 1 in patients with relapsed low-grade non-Hodgkin's lymphoma and chronic lymphocytic leukemia. Clin Cancer Res 2000; 6: 825-828.
27. Kitada S, Zapata JM, Andreeff M, Reed JC. Bryostatin and CD40-ligand enhance apoptosis resistance and induce expression of cell survival genes in B-cell chronic lymphocytic leukaemia. Br J Haematol 1999; 106: 995-1004.
28. Thomas A, Pepper C, Hoy T, Bentley P. Bryostatin induces protein kinase C modulation, Mcl-1 up-regulation and phosphorylation of Bcl-2 resulting in cellular differentiation and resistance to drug-induced apoptosis in B-cell chronic lymphocytic leukemia cells. Leuk Lymphoma 2004; 45: 997-1008.
29. Hammond C, Shi Y, Mena J, et al. Effect of serum and antioxidants on the immunogenicity of protein kinase C-activated chronic lymphocytic leukemia cells. J Immunother 2005; 28: 28-39.
30. Barragán M, Campàs C, Bellosillo B, Gil J. Protein kinases in the regulation of apoptosis in B-cell chronic lymphocytic leukemia. Leuk Lymphoma 2003; 44: 1865-1870.
31. Kitada S, Zapata JM, Andreeff M, Reed JC. Protein kinase inhibitors flavopiridol and 7-hydroxy-staurosporine downregulate antiapoptosis proteins in B-cell chronic lymphocytic leukemia. Blood 2000; 96: 393-397.
32. Snowden RT, Sun XM, Dyer MJ, Cohen GM. Bisindolylmaleimide IX is a potent inducer of apoptosis in chronic lymphocytic leukaemic cells and activates cleavage of Mcl-1. Leukemia 2003; 17: 1981-1989.
33. Escobar-Díaz E, López-Martín EM, Hernández del Cerro M, et al. AT514, a cyclic depsipeptide from Serratia marcescens, induces apoptosis of B-chronic lymphocytic leukemia cells: interference with the Akt/NF-kappaB survival pathway. Leukemia 2005; 19: 572-579.
34. Ganeshaguru K, Wickremasinghe RG, Jones DT, et al. Actions of the selective protein kinase C inhibitor PKC412 on B-chronic lymphocytic leukemia cells in vitro. Haematologica 2002; 87: 167-176.
35. Villalba M, Kasibhatla S, Genestier L, et al. Protein kinase ctheta cooperates with calcineurin to induce Fas ligand expression during activation-induced T cell death. J Immunol 1999; 163: 5813-5819.
36. Leitges M, Elis W, Gimborn K, Huber M. Rottlerin-independent attenuation of pervanadate-induced tyrosine phosphorylation events by protein kinase C-delta in hemopoietic cells. Lab Invest 2001; 81: 1087-1095.
37. Emoto Y, Manome Y, Meinhardt G, et al. Proteolytic activation of protein kinase C delta by an ICE-like protease in apoptotic cells. EMBO J 1995; 14: 6148-6156.
38. Ghayur T, Hugunin M, Talanian RV, et al. Proteolytic activation of protein kinase C delta by an ICE/CED 3-like protease induces characteristics of apoptosis. J Exp Med 1996; 184: 2399-2404.
39. Kedei N, Lundberg DJ, Toth A, et al Characterization of the interaction of ingenol 3-angelate with protein kinase C. Cancer Res 2004; 64: 3243-3255.
40. Hampson P, Chahal H, Khanim F, et al. PEP005, a selective small-molecule activator of protein kinase C, has potent antileukemic activity mediated via the delta isoform of PKC. Blood 2005; 106: 1362-1368.
41. Jones RJ, Sharkis SJ, Miller CB, Rowinsky EK, Burke PJ, May WS. Bryostatin 1, a unique biologic response modifier: anti-leukemic activity in vitro. Blood 1990; 75: 1319-1323.
42. Song MG, Gao SM, Du KM, et al. Nanomolar concentration of NSC606985, a camptothecin analog, induces leukemic-cell apoptosis through protein kinase Cdelta-dependent mechanisms Blood 2005; 105: 3714-3721.
43. Nakagawa N, Soh JW, Michie AM. Subversion of PKCa signaling in hematopoietic progenitor cells results in the generation of a B-CLL-like population in vivo. Cancer Research 2006; 66: 527-534.
44. Jiffar T, Kurinna S, Suck G, et al. PKC alpha mediates chemoresistance in acute lymphoblastic leukemia through effects on Bcl2 phosphorylation. Leukemia 2004; 18: 505-512.
45. Ruvolo PP, Deng X, Carr BK, May WS. A functional role for mitochondrial protein kinase Calpha in Bcl2 phosphorylation and suppression of apoptosis. J Biol Chem 1998; 273: 25436-25442.
46. Michie AM, Nakagawa R. 2005. The link between PKCα regulation and cellular transformation. Immunol Letts 96: 155-162.
47. Hornia A, Lu Z, Sukezane T, et al. Antagonistic effects of protein kinase C alpha and delta on both transformation and phospholipase D activity mediated by the epidermal growth factor receptor. Mol Cell Biol 1999; 19: 7672-7680.